This is likely due to stabilization of the anti-apoptotic MCL-1 protein, a phenomenon previously reported in patients with CLL, DLBCL, or AML who become refractory to venetoclax [25, 29, 73]. This evidence concerns the gene MCL1 and B-cell chronic lymphocytic leukemia.